Chao S. Ji

No. 197, Rui Jin 2nd Road
Shanghai, 200025, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 190 publications

Stapokibart reduces blood eosinophil counts in patients with moderate-to-severe atopic dermatitis: a post-hoc analysis from phase II and phase III clinical trials.

Stapokibart reduces blood eosinophil counts in patients with moderate-to-severe atopic dermatitis: a post-hoc analysis from phase II and phase III clinical trials.

Journal: The Journal of dermatological treatment

Published: July 15, 2026

Stapokibart provides significant improvements in signs and symptoms of atopic dermatitis irrespective of prior systemic treatment: a post-hoc analysis of a phase 3 trial.

Stapokibart provides significant improvements in signs and symptoms of atopic dermatitis irrespective of prior systemic treatment: a post-hoc analysis of a phase 3 trial.

Journal: The Journal of dermatological treatment

Published: July 06, 2026

Dermatitis Artefacta: A Multidisciplinary Approach.

Dermatitis Artefacta: A Multidisciplinary Approach.

Journal: The American journal of case reports

Published: July 04, 2026

Correction: Exploring the role of ferroptosis in pemphigus: identification of diagnostic markers and regulatory mechanisms.

Correction: Exploring the role of ferroptosis in pemphigus: identification of diagnostic markers and regulatory mechanisms.

Journal: Frontiers in medicine

Published: June 04, 2026

Efficacy and Safety of the First Adalimumab Biosimilar in Chinese Children with Severe Plaque Psoriasis: The PISCES Study, a Multicenter Prospective Study.

Efficacy and Safety of the First Adalimumab Biosimilar in Chinese Children with Severe Plaque Psoriasis: The PISCES Study, a Multicenter Prospective Study.

Journal: Dermatology and therapy

Published: June 02, 2026

Efficacy and Safety of Recibokibart, an Interleukin-36 Receptor Antibody, in Generalized Pustular Psoriasis: A Phase 2 Randomized Trial.

Efficacy and Safety of Recibokibart, an Interleukin-36 Receptor Antibody, in Generalized Pustular Psoriasis: A Phase 2 Randomized Trial.

Journal: The British journal of dermatology

Published: May 21, 2026

Screening and Identification of TRPV1-Targeting Peptides from Apis mellifera Venom with Inflammatory Modulatory Potential.

Screening and Identification of TRPV1-Targeting Peptides from Apis mellifera Venom with Inflammatory Modulatory Potential.

Journal: Journal of natural products

Published: April 14, 2026

Multimodal deep learning fusion model for assessment of fetal lung development in gestational diabetes mellitus and pre-eclampsia.

Multimodal deep learning fusion model for assessment of fetal lung development in gestational diabetes mellitus and pre-eclampsia.

Journal: Frontiers in endocrinology

Published: March 17, 2026

Safety and Efficacy of ICP-332 for Moderate to Severe Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.

Safety and Efficacy of ICP-332 for Moderate to Severe Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.

Journal: JAMA dermatology

Published: January 14, 2026

Efficacy and Safety of SSGJ-608 in Moderate-to-Severe Plaque Psoriasis: A Pivotal Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Trial.

Efficacy and Safety of SSGJ-608 in Moderate-to-Severe Plaque Psoriasis: A Pivotal Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Trial.

Journal: American journal of clinical dermatology

Published: January 13, 2026

Combination secukinumab and surgical intervention for moderate-to-severe hidradenitis suppurativa: A retrospective cohort study.

Combination secukinumab and surgical intervention for moderate-to-severe hidradenitis suppurativa: A retrospective cohort study.

Journal: JAAD international

Published: December 22, 2025

Identification of SLIT3 mutation as a response biomarker for immune checkpoint inhibitor therapy in non-small cell lung cancer.

Identification of SLIT3 mutation as a response biomarker for immune checkpoint inhibitor therapy in non-small cell lung cancer.

Journal: Discover oncology

Published: December 22, 2025

Showing 1-12 of 190

Last Updated: 09/26/2026